Blood, Lymphatic, Or Bone Marrow Origin Or Derivative Patents (Class 435/372)
  • Patent number: 10370642
    Abstract: The invention feature methods and compositions for treating hematopoietic disorders, inflammatory conditions, and cancer and providing stem cell therapy in a mammal.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: August 6, 2019
    Inventor: Robert Sackstein
  • Patent number: 10287579
    Abstract: A gene vector for use in gene therapy comprising at least one miRNA sequence target operably linked to a nucleotide sequence having a corresponding miRNA in a hematopoietic progenitor cell (HSPC) or hematopoietic stem cell (HSC) which prevents or reduces expression of the nucleotide sequence in a HSPC or HSC but not in a differentiated cell.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: May 14, 2019
    Assignees: Ospedale San Raffaele S.r.l., Fondazione Telethon
    Inventors: Alessandra Biffi, Bernhard Rudolf Gentner, Luigi Naldini
  • Patent number: 10273503
    Abstract: Methods and compositions for enhancing viral gene transfer, such as lentiviral gene transfer, and improving the efficacy of gene delivery to cells such as primitive hematopoietic cells, are described. These methods and compositions are based on the use of pyrimido[4,5-b]indole derivatives. Cell-based compositions and methods useful for therapeutic indications amenable to treatment with gene therapies, including hematopoietic stem cell therapies, are also described.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: April 30, 2019
    Assignees: UNIVERSITE DE MONTREAL, BRITISH COLUMBIA CANCER AGENCY BRANCH, FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Guy Sauvageau, Keith Richard Humphries, Hans-Peter Kiem, Iman Fares, Jalila Chagraoui
  • Patent number: 10195044
    Abstract: The disclosure relates to an intervertebral disc implant comprising a first construct comprising a continuous layer of nucleus pulposus (NP) tissue directly or indirectly on and integrated with a substrate, and a second construct surrounding the first construct comprising one or more continuous layers of annulus fibrosus (AF) tissue on and adherent to a scaffold, wherein the AF tissue, which is composed of single or multiple adherent layers, is integrated with the NP tissue. The disclosure also relates to methods of preparing the multi-tissue intervertebral disc and using the intervertebral disc as an implant.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: February 5, 2019
    Assignee: Sinai Health System
    Inventors: Rita Kandel, J. Paul Santerre, Shu Qiu Li
  • Patent number: 10188099
    Abstract: The current disclosure provides a method for the creation of a high-density cryopreserved cell bank using perfusion culture techniques and non-centrifugal concentration of cells. Methods of production using this high-density cryopreserved cell bank are also provided.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 29, 2019
    Assignee: GENZYME CORPORATION
    Inventors: Xiaoxia Jin, Haodi Dong, Claudia Buser
  • Patent number: 10184108
    Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: January 22, 2019
    Assignee: Argos Therapeutics, Inc.
    Inventors: Don Healey, Irina Tcherepanova, Melissa Adams, Mark Debenedette
  • Patent number: 10173216
    Abstract: A particle capture system that can be used in the context of a lab-on-a-chip platform for particle- and cell-based assays is described. The system comprises a capture chamber comprising a plurality of capture sites, the capture sites defining a capture area configured to receive individual particles travelling within the capture chamber. By rotating the chamber, the individual particles are biased towards the capture sites where they may be captured.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: January 8, 2019
    Assignee: DUBLIN CITY UNIVERSITY
    Inventors: Jens Ducree, Robert Burger
  • Patent number: 10149897
    Abstract: A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated into or coated onto the scaffold composition such that the scaffold composition and/or a bioactive composition controls egress of a resident cell or progeny thereof. The devices mediate active recruitment, modification, and release of host cells from the material.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: December 11, 2018
    Assignees: President and Fellows of Harvard College, Regents of the University of Michigan
    Inventors: David J. Mooney, Omar Abdel-Rahman Ali, Eduardo Alexandre Barros E Silva, Hyun Joon Kong, Elliot Earl Hill, Jr., Tanyarut Boontheekul
  • Patent number: 10137184
    Abstract: A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated into or coated onto the scaffold composition such that the scaffold composition and/or a bioactive composition controls egress of a resident cell or progeny thereof. The devices mediate active recruitment, modification, and release of host cells from the material.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: November 27, 2018
    Assignees: President and Fellows of Harvard College, Regents of the University of Michigan
    Inventors: David J. Mooney, Omar Abdel-Rahman Ali, Eduardo Alexandre Barros E Silva, Hyun Joon Kong, Elliot Earl Hill, Jr., Tanyarut Boontheekul
  • Patent number: 10004701
    Abstract: Provided herein are compositions and methods for treating or preventing infection.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: June 26, 2018
    Assignees: UNIVERSITY OF ROCHESTER, UNIVERSITY OF KANSAS
    Inventors: Paul M. Dunman, Damian J. Krysan, Daniel P. Flaherty
  • Patent number: 9993503
    Abstract: Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: June 12, 2018
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Qiang Feng, Shi-Jiang Lu, Robert P. Lanza
  • Patent number: 9993537
    Abstract: Certain embodiments of the invention are directed to methods for inducing an immunologic response to a tumor in a patient using mature dendritic cells transfected with a nucleic acid composition encoding one or more tumor antigens and loaded with a corresponding tumor antigen composition.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: June 12, 2018
    Assignee: Board of Regents, The University of Texas System
    Inventors: William K. Decker, Elizabeth J. Shpall, Krishna V. Komanduri, Dongxia Xing
  • Patent number: 9969977
    Abstract: Substantially homogenous cells populations which co-express CD49c, CD90 and telomerase are made. In one embodiment, humans suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition are treated with the substantially homogenous cells populations which co-express CD49c, CD90 and telomerase. In another embodiment, committed progenitor cells are made are made by selecting from a cultured source of a cell population which co-express CD49c and CD90 and modifying the cell population. The committed progenitor cells can be employed to treat a human suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition and to formulate pharmaceutical compositions. In a further embodiment, a substantially homogenous population of cells which co-express CD49c, CD90 and at least one cardiac-related transcription factor is made and can be used to treat a human suffering from a cardiac condition.
    Type: Grant
    Filed: September 20, 2002
    Date of Patent: May 15, 2018
    Assignee: GARNET BIOTHERAPEUTICS
    Inventors: Tony W. Ho, Gene C. Kopen, William F. Righter, J. Lynn Rutkowski, Joseph Wagner, W. Joseph Herring, Vanessa Ragaglia
  • Patent number: 9937208
    Abstract: The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that have one or more of the following effects in an injured subject: interact with splenocytes, preserve splenic mass, increase proliferation of CD4+ and CD8+ T-cells, increase IL-4 and IL-10, decrease IL-6 and IL-1?, and increase M2:M1 macrophage ratio at the site of injury. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to have these effects. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for achieving these effects.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: April 10, 2018
    Assignee: ABT Holding Company
    Inventor: Robert W. Mays
  • Patent number: 9910935
    Abstract: A bioassembly system having a tissue/object modeling software component fully and seamlessly integrated with a robotic bioassembly workstation component for the computer-assisted design, fabrication and assembly of biological and non-biological constructs. The robotic bioassembly workstation includes a six-axis robot providing the capability for oblique-angle printing, printing by non-sequential planar layering, and printing on print substrates having variable surface topographies, enabling fabrication of more complex bio-constructs including tissues, organs and vascular trees.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: March 6, 2018
    Assignee: Advanced Solutions Life Sciences, LLC
    Inventors: Michael Golway, Justin C. Palmer, Jeffrey Kyle Eli, Joshua D. Bartlett, Ellsworth H. Collins
  • Patent number: 9910039
    Abstract: The present specification discloses regulatory T cells, compositions including regulatory T cells, methods of identifying, isolating, enriching, obtaining, and/or expanding regulatory T cells or subset populations thereof, kits including components useful for performing such methods, and methods of treating an immune-based disorder in an individual by administering regulatory T cells or compositions comprising such regulatory T cells to an individual in need thereof.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: March 6, 2018
    Assignee: Beckman Coulter, Inc.
    Inventor: Carlos A. Garcia Santana
  • Patent number: 9834752
    Abstract: The present invention relates to a method for in vitro expansion of mature erythroid cells. More specifically, the present invention relates to a method for obtaining concentrated erythrocytes by culturing erythroid cells at high density so as to allow the cells to physically and directly come in contact with each other. Particularly, the method of the present invention is very useful in that it is possible to obtain a large amount of clinically useful concentrated erythrocytes through a small container such as a test tube-sized bioreactor.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: December 5, 2017
    Assignee: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY
    Inventors: Eun-Jung Baek, Hye-Sook Choi
  • Patent number: 9834755
    Abstract: The present invention relates to methods, kits and compositions for expansion of hematopoietic stem/progenitor cells and providing hematopoietic function to human patients in need thereof. In one aspect, it relates to kits and compositions comprising a Notch agonist and an aryl hydrocarbon receptor antagonist. Also provided herein are methods for expanding the hematopoietic stem/progenitor cells using kits and compositions comprising a Notch agonist and an aryl hydrocarbon receptor antagonist. The hematopoietic stem/progenitor cells expanded using the disclosed kits, compositions and methods include human umbilical cord blood stem/progenitor cells, placental cord blood stem/progenitor cells and peripheral blood stem cells. The present invention also relates to administering hematopoietic stem/progenitor cells expanded using a combination of a Notch agonist and an aryl hydrocarbon receptor antagonist to a patient for short-term and/or long-term in vivo repopulation benefits.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: December 5, 2017
    Assignees: Fred Hutchinson Cancer Research Center, Novartis AG
    Inventors: Irwin D. Bernstein, Anthony E. Boitano, Michael Cooke, Colleen Delaney
  • Patent number: 9783778
    Abstract: The description discloses a device and a kit adapted for selection of cells that are resistant to receptor-mediated apoptosis and a method for using the device and kit. The device enables negative selection of mature immune cells which induce graft versus host disease (GvHD) out of a heterogeneous cell population which is introduced into the device. The device enables an efficient cell selection in simplified and cheaper setting by an off the shelf product—a solution that currently do not exist. The description further discloses uses for the device.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: October 10, 2017
    Assignee: Cellect Biotherapeutics Ltd.
    Inventors: Shai Yarkoni, Nadir Askenasy
  • Patent number: 9764014
    Abstract: Compositions comprising dendritic cells pulsed with tumor lysate and at least one toll-like receptor (TLR) ligand which may be used for eliciting a specific immune response in a mammal in need thereof for treating diseases including a tumor are disclosed. Also disclose are methods of activating dendritic cells, comprising providing at least one toll-like receptor (TLR) ligand; and pulsing a dendritic cell with the at least one TLR ligand. A method further comprises pulsing the dendritic cell with a tumor lysate.
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: September 19, 2017
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Keith L. Black, Dwain Morris-Irvin, Moshe Arditi
  • Patent number: 9733246
    Abstract: The present invention relates to a method for detection, differentiation and quantification of T cell populations, comprising the following steps a) contacting a first aliquot of a body fluid of an individual with at least one antigen, wherein the body fluid contains antigen presenting cells (APC) and T cells, b) incubating the first aliquot with at least one antigen for a certain period of time, c) detection and differentiation of the T cell population by detecting in the first aliquot and in a second aliquot of the body fluid of the individual, which has not been incubated with the at least one antigen, at least a first marker of the APC induced by T cells in a specific T cell population using reverse transcription quantitative real time-time polymerase chain reaction (RT-qPCR), and d) detection and quantification of the T cell population by determining the ratio of the detected marker of the APC of the first aliquot to the second aliquot as well as a kit for performing the method.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: August 15, 2017
    Assignee: LOPHIUS BIOSCIENCES GMBH
    Inventors: Ludwig Deml, Kristina Naumann, Kornelia Schlombs, Sascha Barabas
  • Patent number: 9709549
    Abstract: Method and systems, for processing biological material, that contain a biological material in a vessel; add an aggregating agent to the material in the vessel and allow the material to separate into two or more distinct submaterials; extract one or more of the submaterials from the vessel; automatically transport one or more of the submaterials remaining in the vessel to a filtration device; and collect a resulting target retentate into a target retentate receptacle.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: July 18, 2017
    Assignee: General Electric Company
    Inventors: Nichole Lea Wood, Reginald Donovan Smith, Hongyi Zhou, Liming Yu, Brian David Polizzotti, Peter D. Miller
  • Patent number: 9574003
    Abstract: A method of selecting cells having zero fucose level useful as host cells for expressing recombinant proteins is disclosed. The method comprises: (d) introducing genetic mutations into a population of CHO cells by contacting the cells with a methotrexate (MTX), (e) contacting the population of CHO cells comprising mutated cells with a non-toxic fucose binding agent for an amount of time that allows binding of the fucose binding agent to a fucose moiety on a cell membrane of the population of cells, wherein the amount of time does not allow killing of the cells; and (f) depleting from the population of cells comprising mutated cells, a subpopulation of cells which bind the fucose binding agent, thereby selecting cells useful as host cells for expressing recombinant proteins, the selected cells having zero fucose content. There are also disclosed cells and cell lines useful as host cells for expressing recombinant proteins.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: February 21, 2017
    Assignee: Merck Serono S.A.
    Inventors: Daniel Helman, Meirav Barshimon, Mira Toister-Achituv
  • Patent number: 9550990
    Abstract: Methods are provided for the identification of compounds that selectively modulate epigenetic changes in gene expression. Compounds, compositions, kits or assays devices, and methods are provided for modulating the expression, endogenous levels or the function of small non-coding RNAs cognate to or transcribed by heterochromatic regions subject to epigenetic regulation (i.e., promoters, enhancers, centromeres, telomeres, origins of DNA replication, imprinted loci, or loci marked by dosage-compensation), and for modulating the formation or function of heterochromatin in cells, tissues or animals.
    Type: Grant
    Filed: December 12, 2005
    Date of Patent: January 24, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Richard H. Griffey, Timothy Vickers, Ranjan Perera
  • Patent number: 9523077
    Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: December 20, 2016
    Assignee: Argos Therapeutics, Inc.
    Inventors: Don Healey, Irina Tcherepanova, Melissa Adams, Mark DeBenedette
  • Patent number: 9512402
    Abstract: The invention relates to a method for in vitro maturation of at least one immate dendritic cell, comprising stimulating said immature dendritic cell with TNF?, IL-1?, IFN?, a TLR7/8 agonist and prostaglandin E2(PG). Furthermore, the invention elates to a composition comprising these factors as well as to mature dendritic cells produced by a method of the invention.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: December 6, 2016
    Assignee: Helmholtz Zentrum Munchen Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH)
    Inventors: Dolores J. Schendel, Anke Zobywalski, Iris Bigalke
  • Patent number: 9477906
    Abstract: A method for classifier generation includes a step of obtaining data for classification of a multitude of samples, the data for each of the samples consisting of a multitude of physical measurement feature values and a class label. Individual mini-classifiers are generated using sets of features from the samples. The performance of the mini-classifiers is tested, and those that meet a performance threshold are retained. A master classifier is generated by conducting a regularized ensemble training of the retained/filtered set of mini-classifiers to the classification labels for the samples, e.g., by randomly selecting a small fraction of the filtered mini-classifiers (drop out regularization) and conducting logistical training on such selected mini-classifiers. The set of samples are randomly separated into a test set and a training set.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: October 25, 2016
    Assignee: Biodesix, Inc.
    Inventors: Heinrich Röder, Joanna Röder
  • Patent number: 9476029
    Abstract: Disclosed herein are new methods of producing a novel line of dendritic cells. The method comprises subjecting a sample of hematopoietic stem/precursor cells to a first feeder culture system that is supplemented with a first set of factors and a second feeder culture system supplemented with a second group of factors. The disclosure also pertains to new cell types that may be used as cancer immunotherapy.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: October 25, 2016
    Inventor: Lung-Ji Chang
  • Patent number: 9446107
    Abstract: A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated into or coated onto the scaffold composition such that the scaffold composition and/or a bioactive composition controls egress of a resident cell or progeny thereof. The devices mediate active recruitment, modification, and release of host cells from the material.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: September 20, 2016
    Assignees: President and Fellows of Harvard College, Regents of the University of Michigan
    Inventors: David J. Mooney, Omar Abdel-Rahman Ali, Eduardo Alexandre Barros E Silva, Hyun Joon Kong, Elliot Earl Hill, Jr., Tanyarut Boontheekul
  • Patent number: 9428748
    Abstract: Described is a method of expanding hematopoietic stem or progenitor cells. The invention further includes a method of treating primary or secondary bone marrow failure syndrome.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: August 30, 2016
    Inventors: Hong Gao, Zhenglun Zhu
  • Patent number: 9402388
    Abstract: The invention is directed to a method of freezing stem cells comprising introducing the HSCs into a cell culture medium that has been conditioned with Wharton's Jelly mesenchymal stem cells (WJSCs), thereby producing a stem cell culture, and slowly freezing the stem cell culture. In other aspects, the invention is directed to compositions comprising stem cells produced by the methods provided herein. In yet other aspects, the invention is directed to pharmaceutical compositions comprising the stem cells produced by the methods provided herein.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: August 2, 2016
    Assignee: National University of Singapore
    Inventors: Chui Yee Fong, Tuan Ariffeen Bongso, Daniel Hao Lin
  • Patent number: 9376483
    Abstract: Fibronectin Type III (FN3) polypeptide libraries are described, along with their use in identifying fibronectin-type binding peptides having high binding affinities, e.g., greater than 300 nM, for VEGFR2 or Axl proteins.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: June 28, 2016
    Assignee: Protelica, Inc.
    Inventors: Guido Cappuccilli, Roberto Crea, Randy Shen, Craig A. Hokanson, Peter B. Kirk, David R. Liston
  • Patent number: 9333248
    Abstract: Certain embodiments of the invention are directed to methods for inducing an immunologic response to a tumor in a patient using mature dendritic cells transfected with a nucleic acid composition encoding one or more tumor antigens and loaded with a corresponding tumor antigen composition.
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: May 10, 2016
    Assignee: Board of Regents, The University of Texas System
    Inventors: William K. Decker, Elizabeth J. Shpall, Krishna V. Komanduri, Dongxia Xing
  • Patent number: 9314439
    Abstract: The invention provides methods for muscle repair or regeneration comprising administering therapeutically effective amounts of RAR agonists or stem cells that are pretreated with contact with a RAR agonist to a subject at a site of muscle damage. Additionally, the invention provides compositions comprising RAR agonist treated stem cells and methods of use of said cells for muscle repair or regeneration. In one embodiment, the stem cells are mesenchymal stem cells. In one embodiment, the RAR agonist is an RAR? agonist. In one embodiment, administration of the RAR agonist is begun during a period of increased endogenous retinoid signaling in the subject resulting from incurrence of the damaged muscle tissue.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: April 19, 2016
    Assignee: Thomas Jefferson University
    Inventors: Masahiro Iwamoto, Maurizio Pacifici
  • Patent number: 9234174
    Abstract: The present invention relates to a tolerogenic dendritic cell population (Tr-DC) capable of generating a population of T cells having regulatory activity, method of production and uses thereof. Furthermore, soluble HLA-G promotes the differentiation of a population of T cells with regulatory activity.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: January 12, 2016
    Assignees: OSPEDALE SAN RAFFAELE S.R.L., FONDAZIONE TELETHON
    Inventors: Silvia Adriana Gregori, Maria Grazia Roncarolo, Rosa Bacchetta
  • Patent number: 9228172
    Abstract: The present invention provides methods and compositions for converting non-Tregs into Tregs. The converted Tregs are referred to as inducible Tregs (iTregs). The iTregs are useful for preventing, suppressing, blocking or inhibiting an immune response. For example the iTregs are useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft vs host disease. The iTregs can also be used to treat autoimmune diseases.
    Type: Grant
    Filed: June 19, 2009
    Date of Patent: January 5, 2016
    Assignees: The Trustees of the University of Pennsylvania, Regents of the University of Minnesota
    Inventors: James L. Riley, Carl H. June, Bruce R. Blazar, Keli Hippen
  • Patent number: 9226942
    Abstract: A method of expanding hematopoietic stem cells. Also disclosed is a method of diagnosing primary or secondary bone marrow failure syndrome. The invention further includes a method of treating primary or secondary bone marrow failure syndrome.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: January 5, 2016
    Inventors: Hong Gao, Zhenglun Zhu
  • Patent number: 9200253
    Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.
    Type: Grant
    Filed: August 6, 2008
    Date of Patent: December 1, 2015
    Assignee: Anthrogenesis Corporation
    Inventors: Mohammad A. Heidaran, Xiaokui Zhang, Lin Kang, Andrew Zeitlin, Vanessa R. Voskinarian-Berse, Stewart Ernest Abbott
  • Patent number: 9161971
    Abstract: The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: October 20, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce Levine, Anne Chew, Stephen J. Schuster
  • Patent number: 9132210
    Abstract: A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated into or coated onto the scaffold composition such that the scaffold composition and/or a bioactive composition controls egress of a resident cell or progeny thereof. The devices mediate active recruitment, modification, and release of host cells from the material.
    Type: Grant
    Filed: March 24, 2014
    Date of Patent: September 15, 2015
    Assignees: President and Fellows of Harvard College, Regents of the University of Michigan
    Inventors: David J. Mooney, Omar Abdel-Rahman Ali, Eduardo Alexandre Barros E Silva, Hyun Joon Kong, Elliot Earl Hill, Jr., Tanyarut Boontheekul
  • Patent number: 9133505
    Abstract: The invention relates to methods and kits for the quantitative analysis of in vivo mutation frequencies of the Pig-A gene in individuals, particularly using peripheral blood samples of vertebrates.
    Type: Grant
    Filed: November 23, 2011
    Date of Patent: September 15, 2015
    Assignee: Litron Laboratories, Ltd.
    Inventors: Stephen D. Dertinger, Steven M. Bryce
  • Patent number: 9125876
    Abstract: Use of erythrocytes containing arginine deirainase for the preparation of a medicinal product for lowering the plasma concentration of arginine in vivo. The use relates in particular to the treatment of arginine-dependent tumors, such as hepatocarcinoma and malignant melanoma, or inhibition of the synthesis of nitric oxide, and the prevention and/or treatment of septic shock.
    Type: Grant
    Filed: April 25, 2006
    Date of Patent: September 8, 2015
    Assignee: ERYTECH PHARMA
    Inventors: Yann Godfrin, Pierre-Olivier Goineau
  • Patent number: 9114100
    Abstract: Provided are methods of enhancing ex vivo proliferation of a T cell population, the methods comprising contacting the T cell population with IL-7 and anti-CD3/CD28 antibody to activate and expand the T cell population. Further provided are methods of generating an antigen-specific cytotoxic T cell population comprising priming a CD3/CD28-expanded T cell population against an antigen (e.g., a cancer cell) in the presence of at least one of IL-7, IL-12, and IL-15, or a combination thereof. Further provided are methods of treating T cell lymphopenia in a subject, comprising administering a CD3/CD28-expanded T cell population to the subject.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: August 25, 2015
    Assignee: Duke University
    Inventor: Paul Szabolcs
  • Patent number: 9097702
    Abstract: A three-dimensional cell culture system is provided comprising one or more cell types of interest incorporated in a natural or synthetic hydrogel. An apparatus for high-throughput drug screening is also provided comprising a plurality of three-dimensional cell culture systems and a dispenser for placing at least one three-dimensional cell culture system into a pre-determined well of a multiwell plate. A method for high-throughput drug screening is also provided that comprises providing a test agent, providing a three-dimensional cell culture system, determining a first cellular response of the cell of interest before culturing in the presence of the agent, culturing the cell of interest in the cell culture system in the presence of the agent, determining a second cellular response of the cell of interest after culturing in the presence of the agent, and comparing the first and second cellular responses.
    Type: Grant
    Filed: July 28, 2009
    Date of Patent: August 4, 2015
    Assignee: Cornell University
    Inventor: Claudia Fischbach
  • Patent number: 9056080
    Abstract: The presently disclosed subject matter provides methods for increasing perfusion in hypoxic regions of tissues in subjects. Also provided are methods for treating diseases and/or disorders associated with hypoxia in subjects, methods for increasing sensitivity of tumors to radiation and/or chemotherapy treatments, methods for delaying tumor growth in subjects, and methods for inhibiting tumor blood vessel growth in subjects. In some embodiments, the presently disclosed methods involve administering to subjects in need thereof a first composition selected from the group consisting of a nitrosylated hemoglobin and an agent that induces nitrosylation of endogenous hemoglobin in the subject and a second composition comprising a hyperoxic gas. In some embodiments, the presently disclosed methods also include treating a tumor with radiation therapy, chemotherapy, photodynamic therapy, immunotherapy, or combinations thereof. Also provided are inhalable gases that can be employed in the presently disclosed methods.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: June 16, 2015
    Assignee: Duke University
    Inventors: Mark W. Dewhirst, Jonathan S. Stamler, Timothy J. McMahon, Pierre D. Sonveaux
  • Patent number: 9034922
    Abstract: A composition for maintaining a function of platelets, the composition comprising, as an active ingredient, a compound represented by the following general formula (I) or a salt thereof, or a solvate thereof: wherein X represents a phenylene group; Y represents any one of a hydrogen atom and —(CH2)mR1; wherein m represents an integer of any one of 0 to 4; and R1 is any one of —NR5COR2, —NR5SO2R2, and —NR3R4; wherein R2 represents any one of a C1 to C6 alkyl group, an aryl group, a C1 to C6 alkoxy group, and the like; R3 and R4 represent a C1 to C6 alkyl group or the like; and R5 represents any one of a hydrogen atom, a C1 to C6 alkyl group, and the like; and Z represents any one of a hydrogen atom and a C1 to C6 alkyl group.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: May 19, 2015
    Assignees: THE UNIVERSITY OF TOKYO, KAKEN PHARMACEUTICAL CO., LTD.
    Inventors: Koji Eto, Ryoko Ohnishi, Hiromitsu Nakauchi, Takahiko Murata
  • Patent number: 9034644
    Abstract: Tissue repair compositions, particularly bone repair compositions, containing demineralized bone fragments and homogenized connective tissues, and methods for making the same. The compositions can be used in the form of an injectable gel, an injectable paste, a paste, a putty, or a rehydratable freeze-dried form.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: May 19, 2015
    Assignee: LifeNet Health
    Inventors: Leila Masinaei, Lloyd Wolfinbarger, Jr.
  • Patent number: 9034317
    Abstract: This invention pertains to cancer immunotherapy, by providing a proinflammatory dendritic cell (DC), which has been stimulated to maturation ex vivo by specific treatment, a method for such treatment and a composition comprising the proinflammatory DC. The DC may be used as a cell based immunotherapy for inhibiting tumor cell proliferation.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: May 19, 2015
    Assignee: IMMUNICUM AB
    Inventors: Alex Karlsson-Parra, Bengt Andersson, AnnaCarin Wallgren
  • Publication number: 20150132844
    Abstract: Methods are provided for the production of dendritic cells from monocytes that have been incubated at a temperature of 1° C.-34° C. for a period of approximately 6 to 96 hours from the time they are isolated from a subject. After the incubation period, the monocytes can then be induced to differentiate into dendritic cells. Mature dendritic cells made by the methods of the invention have increased levels of one or more of CD80, CD83, CD86, MHC class I molecules, or MHC class II molecules as compared to mature dendritic cells prepared from monocytes that have not been held at 1° C.-34° C. for at least 6 hours from the time they were isolated from a subject. Dendritic cells made by the methods of the invention are useful for the preparation of vaccines and for the stimulation of T cells.
    Type: Application
    Filed: June 18, 2014
    Publication date: May 14, 2015
    Inventors: Rebecca POGUE, Tamara Monesmith, Irina Tcherepanova, Lois Dinterman
  • Publication number: 20150132853
    Abstract: Methods for de-differentiating or altering the life-span of desired “recipient” cells, e.g., human somatic cells, by the introduction of cytoplasm from a more primitive, less differentiated cell type, e.g., oocyte or blastomere are provided. These methods can be used to produce embryonic stem cells and to increase the efficiency of gene therapy by allowing for desired cells to be subjected to multiple genetic modifications without becoming senescent. Such cytoplasm may be fractionated and/or subjected to subtractive hybridization and the active materials (sufficient for de-differentiation) identified and produced by recombinant methods.
    Type: Application
    Filed: June 11, 2014
    Publication date: May 14, 2015
    Applicant: Advanced Cell Technology, Inc.
    Inventor: Karen B. Chapman